Genitourinary Cancers Steering Committee
The Genitourinary Steering Committee (GUSC) was established in 2008. The GUSC is currently composed of the Steering Committee and three task forces (Prostate Cancer, Bladder Cancer, and Renal Cancer). Members of the GUSC include representatives from the Cooperative Groups with active genitourinary programs, representatives from the prostate, renal, and bladder Specialized Programs of Research Excellence (SPORE) and other translational scientists, community oncologists, biostatisticians, pathologists, patient advocates, and NCI staff.
The GUSC functions to harmonize an efficient, cost-effective, science-driven, and transparent process that will identify and promote the "Best Science" in genitourinary cancer clinical research by addressing the design and prioritization of phase III trials and large phase II studies.
Roster of Genitourinary Steering Committee (GUSC) members
Robert Dreicer, M.D., Eric Klein, M.D., and Anthony Zietman, M.D., Co-chairs
- Prostate Cancer: Deborah A. Kuban, M.D., Charles J. Ryan, M.D., Andrew Stephenson, M.D. Co-chairs
- Bladder Cancer: Dean Bajorin, M.D., Jason A. Efstathiou, M.D., Ph.D. and Seth Lerner, M.D. Co-chairs
- Renal Cancer: Christopher Kane, M.D., Brian Rini, M.D., Victor Reuter, M.D. Co-chairs
Clinical Trials Planning Meetings (CTPMs)
The Goal of CTPMs is to:
- identify strategic directions for clinical trials in a specific field
- reach consensus on the most important clinical trials to conduct;
- identify portfolio gaps and emerging scientific opportunities;
- identify innovative trial design opportunities;
- facilitate innovation and collaboration among the broad oncology community active in the specific cancer under study
- RTOG-0815: A Phase III Prospective Randomized Trial of Dose-Escalated Radiotherapy with or without Short-Term Androgen Deprivation Therapy for Patients with Intermediate-Risk Prostate Cancer (NCT00936390)
- CALGB-90802: Randomized Phase III Trial Comparing Everolimus Plus Placebo versus Everolimus Plus Bevacizumab for Advanced Renal Cell Carcinoma Progressing After Treatment with Tyrosine Kinase Inhibitors (NCT01198158)
- ECOG-2810: Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Subjects with Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastasectomy (NCT01575548)
To search all active clinical trials, go to: http://www.cancer.gov/clinicaltrials/search
CCCT Contact: Abdul Tawab-Amiri, Ph.D.